QMS Medical Q2 FY26 Earnings Analysis

- QMS Medical Allied Services aims for strong growth by leveraging its leadership in B2B pharma promotion and patient service programs. - Q-Devices wellness products expected to grow from Rs. 10 crores in Q1 FY'26 to a conservative target of Rs. 25 crores in FY'26. - Services business (including Saarathi acquisition) targets 50% year-on-year growth, expecting to cross Rs. 60 crores revenue combining QMS and Saarathi. - The company plans to expand patient service programs and CAMS into new sectors like corporate healthcare and government programs. - QMS aims to increase market share in the emerging patient service program space, estimated globally at $70 billion. - Focus on enhancing distribution through non-traditional channels like CSC and e-Grameen for wellness products. - Pursuing inorganic growth opportunities in B2B and services sectors to accelerate revenue growth.

- QMS Medical Allied Services aims for robust growth with a focus on expanding services, especially in patient service programs and CAMS. - The services segment, including Saarathi, is targeted to grow by 50% year-on-year. - For FY '26, Q-Devices (B2C wellness products) is expected to achieve at least Rs. 25 crores in revenue, up from Rs. 10 crores in Q1 alone. - The combined services revenue (QMS + Saarathi) is expected to cross Rs. 60 crores with higher margins, as services have roughly double the margins of products. - The company targets further inorganic growth opportunities in the pharma promotion sector. - Consistent improvement in EBITDA and profit after tax was shown in Q1 FY '26; management is confident in continuing this upward trend. - The company focuses on accountability, innovation, efficiency, and expanding its institutional client base, targeting higher earnings and stakeholder value creation.

The transcript does not explicitly mention any current or future capex or capital investment plans. However, the following points provide some insight related to strategic investments: - QMS Medical Allied Services Limited acquired a controlling 51% stake in Saarathi for Rs. 45 crores, with plans to acquire an additional 49% in two tranches by September 2025 and September 2026 at valuations based on EBITDA multiples. - The company is actively engaged in inorganic growth discussions and strategic acquisitions within the B2B pharma promotion and patient services segment to expand presence. - Focus on expanding the product portfolio, including wellness products under the Q-Devices brand, and expanding distribution through online channels and the e-Grameen network. - Investment in building capabilities, such as hiring over 250 employees and expanding service offerings including patient service programs and CAMS. No explicit capital expenditure or new strategic investments beyond these are detailed in the available transcript.

- There is no direct mention of any ongoing or planned fundraising through debt or equity in the provided transcript. - The company discusses inorganic growth opportunities, including acquisitions and discussions in the B2B segment, but no explicit reference to raising funds via debt or equity. - The acquisition of Saarathi was a cash transaction, with payment in tranches, but this deal seems already completed. - Management emphasizes growth through operational performance and market expansion rather than fundraising at this time. - For further details or updates, investors are invited to contact the IR team. No explicit current or future fundraising plan via debt or equity has been disclosed in this transcript.

- There is no specific mention of the current or expected order book or pending orders in the transcript. - However, it is noted that QMS's B2C wellness products (Q-Devices) achieved Rs. 10 crores revenue in Q1 FY'26, with a conservative full-year target of Rs. 25 crores, indicating ongoing and expected sales orders. - The company is enrolled as a healthcare vendor on the e-Grameen portal, which offers substantial potential to expand product distribution and generate new orders. - The patient service programs and CAMS business, including Saarathi acquisition, are growing with a target to grow services revenue by 50% annually. - Institutional client base includes over 130 clients including top 50 pharma companies across 5,000+ pin codes, implying steady service orders. - New projects like the Humrahi program contribute around 6%-7% of turnover, suggesting ongoing service engagement orders.